Study to Investigate the Efficacy of Symbicort® SMART. (SAKURA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00839800
First received: February 4, 2009
Last updated: November 26, 2012
Last verified: November 2012
  Purpose

The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy


Condition Intervention Phase
Asthma
Drug: Symbicort Turbuhaler
Drug: Terbutaline Turbuhaler
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study [ Time Frame: week 52 ] [ Designated as safety issue: No ]
    Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment.


Secondary Outcome Measures:
  • Number of Asthma Exacerbations [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]
    Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.

  • Morning Peak Expiratory Flow (PEF) [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    The mean value from a 52-week treatment period.

  • Evening PEF [ Time Frame: 2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period ] [ Designated as safety issue: No ]
    The mean value from a 52-week treatment period.

  • Forced Expiratory Volume in One Second (FEV1) [ Time Frame: 4, 12, 24, 36 and 52 weeks after randomization ] [ Designated as safety issue: No ]
    The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.

  • Use of As-needed Medication [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).

  • Asthma Symptom Score [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).

  • Nights With Awakening(s) Due to Asthma Symptoms [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    The mean value from the treatment period was presented here.

  • The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations [ Time Frame: up to 52 weeks ] [ Designated as safety issue: No ]
    Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.

  • Symptom-free Days (no Symptoms and no Awakenings) [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.

  • Percentage of As-needed-free Days [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.

  • Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use) [ Time Frame: 52-week treatment period ] [ Designated as safety issue: No ]
    An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.

  • Asthma Control Questionnaire (ACQ) [ Time Frame: 4, 12, 24, 36 and 52 weeks after randomization ] [ Designated as safety issue: No ]
    The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.


Enrollment: 2091
Study Start Date: February 2009
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
Drug: Symbicort Turbuhaler
160/4.5 µg
Active Comparator: 2
Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
Drug: Symbicort Turbuhaler
160/4.5 µg
Drug: Terbutaline Turbuhaler
0.4 mg

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration.
  • Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler
  • Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks.

Exclusion Criteria:

  • Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks.
  • Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00839800

  Hide Study Locations
Locations
Argentina
Research Site
Capital Federal, Buenos Aires, Argentina
Research Site
Mar Del Plata, Buenos Aires, Argentina
Research Site
Monte Grande, Buenos Aires, Argentina
Research Site
Quilmes, Buenos Aires, Argentina
Research Site
Rosario, Santa Fe, Argentina
Research Site
San Miguel de Tucuman, Tucuman, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Santa Fe, Argentina
Brazil
Research Site
Porto Alegre, Brasil, Brazil
Research Site
Belo Horizonte, MG, Brazil
Research Site
Juiz de Fora, MG, Brazil
Research Site
Rio de Janeiro, RJ, Brazil
Research Site
Porto Alegre, RS, Brazil
Research Site
Florianopolis, Santa Catarina, Brazil
Research Site
Santo Andre, SP, Brazil
China, Liaoning
Research Site
Shenyang, Liaoning, China
China, Zhejiang
Research Site
Hangzhou, Zhejiang, China
China
Research Site
Chongqing, China
Research Site
Guang Zhou, China
Research Site
Nanjing, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Xi An, China
Costa Rica
Research Site
Tres Rios, Cartago, Costa Rica
Research Site
Barrio San Bosco, San Jose, Costa Rica
Hungary
Research Site
Budapest, Hungary
Research Site
Cegled, Hungary
Research Site
Debrecen, Hungary
Research Site
Deszk, Hungary
Research Site
Gyula, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Szazhalombatta, Hungary
India
Research Site
Bangalore, Karnataka, India
Research Site
Mangalore, Karnataka, India
Research Site
Mysore, Karnataka, India
Research Site
Trivandrum, Kerala, India
Research Site
Mumbai, Maharashtra, India
Research Site
Nagpur, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
Jaipur, Rajasthan, India
Research Site
Coimabatore, Tamilnadu, India
Research Site
Noida, India
Japan
Research Site
Komaki, Aichi, Japan
Research Site
Seto, Aichi, Japan
Research Site
Asahi, Chiba, Japan
Research Site
Matsuyama, Ehime, Japan
Research Site
Kitakyusyu, Fukuoka, Japan
Research Site
Yanagawa, Fukuoka, Japan
Research Site
Isesaki, Gunma, Japan
Research Site
ORA, Gunma, Japan
Research Site
Fukuyama, Hiroshima, Japan
Research Site
Hiroshima-shi, Hiroshima, Japan
Research Site
Asahikawa, Hokkaido, Japan
Research Site
Chitose, Hokkaido, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Tomakomai, Hokkaido, Japan
Research Site
AKO, Hyogo, Japan
Research Site
Himeji, Hyogo, Japan
Research Site
Kobe-city, Hyogo, Japan
Research Site
Hitachi, Ibaraki, Japan
Research Site
Naka-gun, Ibaraki, Japan
Research Site
Morioka, Iwate, Japan
Research Site
Sakaide, Kagawa, Japan
Research Site
Kawasaki, Kanagawa, Japan
Research Site
Kawasaki-shi, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Sendai, Miyagi, Japan
Research Site
Nagaoka, Niigata, Japan
Research Site
Beppu, Oita, Japan
Research Site
Kurashiki, Okayama, Japan
Research Site
Sakai, Osaka, Japan
Research Site
Matsue, Shimane, Japan
Research Site
Utsunomiya, Tochigi, Japan
Research Site
Chuo, Tokyo, Japan
Research Site
Itabashi, Tokyo, Japan
Research Site
Kodaira, Tokyo, Japan
Research Site
Kokubunji, Tokyo, Japan
Research Site
Machida, Tokyo, Japan
Research Site
Nakano-ku, Tokyo, Japan
Research Site
Toshima-ku, Tokyo, Japan
Research Site
Fukuoka, Japan
Research Site
Kagoshima, Japan
Research Site
Kochi, Japan
Research Site
Kyoto, Japan
Research Site
Niigata, Japan
Research Site
Oita, Japan
Research Site
Okayama, Japan
Korea, Republic of
Research Site
Bucheon, Korea, Republic of
Research Site
Cheongju, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Research Site
Suwon, Korea, Republic of
Malaysia
Research Site
Kubang Kerian, Kelantan, Malaysia
Research Site
Kuantan, Pahang, Malaysia
Research Site
Batu Caves, Selangor, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Penang, Malaysia
Peru
Research Site
Surco, Lima, Peru
Research Site
Lima, Peru
Philippines
Research Site
Lipa City, Batangas, Philippines
Research Site
Davao City, Philippines
Research Site
Iloilo City, Philippines
Research Site
Manila, Philippines
Research Site
Quezon City, Philippines
Thailand
Research Site
Bangkoknoi, Bangkok, Thailand
Research Site
Naimuang, Nakhonratchasima, Thailand
Research Site
Hat Yai, Songkla, Thailand
Research Site
Bangkok, Thailand
Research Site
Khon Kaen, Thailand
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Tomas Andersson, MD AstraZeneca R&D Lund
Principal Investigator: Tito Atienza, M.D. Mary Mediatrix Medical Center, Lipa City, Philippines
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00839800     History of Changes
Other Study ID Numbers: D589LC00001
Study First Received: February 4, 2009
Results First Received: February 21, 2012
Last Updated: November 26, 2012
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: National Health Surveillance Agency
China: Ministry of Health
China: Food and Drug Administration
Costa Rica: CEC-UCIMED
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India
Japan: Ministry of Health, Labor and Welfare
Malaysia: Ministry of Health
Philippines: Bureau of Food and Drugs
Russia: Ministry of Health of the Russian Federation
South Korea: Korea Food and Drug Administration (KFDA)
Thailand: Ethical Committee

Keywords provided by AstraZeneca:
Asthma
Symbicort Turbuhaler

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Terbutaline
Budesonide
Symbicort
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Sympathomimetics
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Glucocorticoids

ClinicalTrials.gov processed this record on July 22, 2014